OncoMatch/Clinical Trials/NCT06151080
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Is NCT06151080 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Lenalidomide combined with G-CHOP (LO CHOP) for dlbcl - diffuse large b cell lymphoma.
Treatment: Lenalidomide combined with G-CHOP (LO CHOP) — To evaluate the efficacy and adverse effects of lenalidomide combined with G-CHOP(LO-CHOP) in the treatment of newly diagnosed diffuse large B-cell lymphoma with follicular lymphoma (CDLBCL-FL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC ≥1.0 × 10^9/L, PLT ≥100 × 10^9/L, HGB ≥80 g/L; if myeloma involved: ANC ≥0.75 × 10^9/L, PLT ≥50 × 10^9/L, HGB not required
Kidney function
serum CR ≤2.0 × ULN (unless caused by lymphoma)
Liver function
serum bilirubin ≤2.0 × ULN, serum ALT and AST ≤2.5 × ULN (unless caused by lymphoma)
Cardiac function
Left ventricular ejection fraction (LVEF) was less than 45%
Normal major organ function: liver function: serum bilirubin ≤2.0 × ULN, serum ALT and AST ≤2.5 × ULN, renal function: serum CR ≤2.0 × ULN; (unless caused by lymphoma) Absolute neutrophil count (ANC)≥1.0 × 10^9 l, platelet count (PLT)≥100 × 10^9 L, hemoglobin content (HGB)≥80 g L, if myeloma was involved, ANC ≥0.75 × 10^9 L, platelet count (PLT)≥50 × 10^9 L, HGB content (HGB) was not required. Left ventricular ejection fraction (LVEF) was less than 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06151080 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III or IV is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify